Advertisement

Search Results

Advertisement



Your search for Emily A. Kuhl, PhD matches 5 pages

Showing 1 - 5


breast cancer
immunotherapy

Guideline Update Offers New Directions About Trastuzumab Emtansine for HER2-Positive Breast Cancer

About 10% to 20% of newly diagnosed breast cancers demonstrate overexpression of the HER2 protein.1 Since the introduction of trastuzumab, several new HER2-targeted therapies have been approved for use in the adjuvant and metastatic settings (eg, pertuzumab, lapatinib, and neratinib). However, for...

supportive care
symptom management

Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy

Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...

breast cancer
genomics/genetics

Joint Guideline Sheds Light on Management of Hereditary Breast Cancer

As germline genetic testing becomes more widespread among patients with breast cancer, recommendations for the appropriate management of patients with hereditary breast cancer are needed. Until now, no ASCO guideline has addressed the management of hereditary breast cancer, even for carriers of...

breast cancer

New ASCO Guideline Highlights the Management of Male Breast Cancer

THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...

prostate cancer

Novel Guideline Addresses the Clinical Utility of Molecular Biomarkers in Localized Prostate Cancer

In men, prostate cancer has the highest incidence of any neoplasm and is the second-leading cause of cancer-related mortality. A plethora of tissue-based biomarkers are available to inform the diagnosis and prognosis for men with newly diagnosed, clinically localized prostate cancer. However, to...

Advertisement

Advertisement



Advertisement